Danone and Michelin open a shared €20m fermentation scale-up site in Clermont-Ferrand
Danone and Michelin open a shared €20m fermentation scale-up site in Clermont-Ferrand that start-ups and industry can rent for pilot runs.
Biotech Open Platform, known as BIOP, was inaugurated on 29 September 2026 at the Sustainable Materials Center inside Michelin's Cataroux innovation park in Clermont-Ferrand, France. Danone says more than €20 million has gone into the site in its first phase. The founding consortium is Danone, Michelin, the US biomanufacturer DMC Biotechnologies, Crédit Agricole Centre France, the technology transfer company Clermont Auvergne Innovation and the French biotech group Greentech. The partnership was first announced in 2024; this is the point at which the steel is running.
The specification is the story. Danone's release puts fermentation capacity at up to 15 m³. NutraIngredients reports a 5,000 m² pilot facility with two fully equipped microbial fermentation lines, a downstream processing platform and an analytical laboratory, with purification built to semi-industrial, food-grade standards. BIOP operates as a contract development and manufacturing organisation, so third parties book the capacity and the founding companies' process engineers come with it. World Bio Market Insights reports that the European Regional Development Fund and local public bodies contributed to the build.
The gap being addressed is specific and well documented. “Biotech Open Platform was created to address a very concrete challenge in biotechnology: how to move from a promising process at laboratory scale to a robust process that can work at industrial scale,” said Khadidja Romari, chief executive of Biotech Open Platform. Jim Flatt, chief executive of DMC Biotechnologies, said the platform “provides a concrete response to this challenge by giving companies access to the infrastructure and expertise needed to accelerate the industrialization of biology-based innovations.” Philippe Teissier, research and innovation director at Danone, told NutraIngredients the ambition is for BIOP to become the hub of a biotechnology ecosystem that strengthens European industrial capability.
The membership explains the economics. “With Biotech Open Platform, we are strengthening a critical link in Europe's biotechnology ecosystem by accelerating the industrial scale-up of laboratory innovations,” said Antoine de Saint-Affrique, chief executive of Danone. Florent Menegaux, chairman of Michelin Group, said that by providing companies with an open infrastructure and leading expertise, “we want to accelerate the transition from research to industry.” Frédéric Baraut, chief executive of Crédit Agricole Centre France, framed the bank's involvement as building a structuring asset for innovation, employment and the economic attractiveness of the region. A dairy group, a tyre maker and a regional bank are paying for the same fermenters because proteins, vitamins and fibres for food and biosourced materials for industry need the same unit operations.
What this means for AgTech founders: this is a supply-side correction to a funding pattern that has killed a lot of good fermentation companies. The familiar failure is a team with working strain and lab-scale titres raising a large round to buy its own steel, then spending three years and most of the money learning that a process tuned in a 5-litre vessel behaves differently at 15 m³, and learning it on equipment it now has to keep busy. Shared capacity changes the ask. If you can rent 15 m³ with food-grade downstream and borrowed process engineers, the round you need is for process work and offtake, not for a plant, and that is a smaller, cleaner round that leaves you owning more of the company. Two cautions. 15 m³ is demo scale, not commercial scale, so BIOP de-risks the transfer but does not remove the eventual 100 m³-plus decision; plan the next step before you need it. And downstream, not fermentation, is where most food-grade processes actually break, so the purification train and the analytical lab here are worth more than the fermenter volume in the headline. Budget your time at a shared site accordingly: book it for the recovery problem, not for the growth curve you have already solved.
Danone and Michelin open a shared €20m fermentation scale-up site in Clermont-Ferrand
Biotech Open Platform started operating on 29 September with fermentation capacity of up to 15 m³ and food-grade downstream processing, and sells that capacity to outside companies rather than keeping it for its founders.
Biotech Open Platform, known as BIOP, was inaugurated on 29 September 2026 at the Sustainable Materials Center inside Michelin's Cataroux innovation park in Clermont-Ferrand, France. Danone says more than €20 million has gone into the site in its first phase. The founding consortium is Danone, Michelin, the US biomanufacturer DMC Biotechnologies, Crédit Agricole Centre France, the technology transfer company Clermont Auvergne Innovation and the French biotech group Greentech. The partnership was first announced in 2024; this is the point at which the steel is running.
The specification is the story. Danone's release puts fermentation capacity at up to 15 m³. NutraIngredients reports a 5,000 m² pilot facility with two fully equipped microbial fermentation lines, a downstream processing platform and an analytical laboratory, with purification built to semi-industrial, food-grade standards. BIOP operates as a contract development and manufacturing organisation, so third parties book the capacity and the founding companies' process engineers come with it. World Bio Market Insights reports that the European Regional Development Fund and local public bodies contributed to the build.
The gap being addressed is specific and well documented. “Biotech Open Platform was created to address a very concrete challenge in biotechnology: how to move from a promising process at laboratory scale to a robust process that can work at industrial scale,” said Khadidja Romari, chief executive of Biotech Open Platform. Jim Flatt, chief executive of DMC Biotechnologies, said the platform “provides a concrete response to this challenge by giving companies access to the infrastructure and expertise needed to accelerate the industrialization of biology-based innovations.” Philippe Teissier, research and innovation director at Danone, told NutraIngredients the ambition is for BIOP to become the hub of a biotechnology ecosystem that strengthens European industrial capability.
The membership explains the economics. “With Biotech Open Platform, we are strengthening a critical link in Europe's biotechnology ecosystem by accelerating the industrial scale-up of laboratory innovations,” said Antoine de Saint-Affrique, chief executive of Danone. Florent Menegaux, chairman of Michelin Group, said that by providing companies with an open infrastructure and leading expertise, “we want to accelerate the transition from research to industry.” Frédéric Baraut, chief executive of Crédit Agricole Centre France, framed the bank's involvement as building a structuring asset for innovation, employment and the economic attractiveness of the region. A dairy group, a tyre maker and a regional bank are paying for the same fermenters because proteins, vitamins and fibres for food and biosourced materials for industry need the same unit operations.
What this means for AgTech founders: this is a supply-side correction to a funding pattern that has killed a lot of good fermentation companies. The familiar failure is a team with working strain and lab-scale titres raising a large round to buy its own steel, then spending three years and most of the money learning that a process tuned in a 5-litre vessel behaves differently at 15 m³, and learning it on equipment it now has to keep busy. Shared capacity changes the ask. If you can rent 15 m³ with food-grade downstream and borrowed process engineers, the round you need is for process work and offtake, not for a plant, and that is a smaller, cleaner round that leaves you owning more of the company. Two cautions. 15 m³ is demo scale, not commercial scale, so BIOP de-risks the transfer but does not remove the eventual 100 m³-plus decision; plan the next step before you need it. And downstream, not fermentation, is where most food-grade processes actually break, so the purification train and the analytical lab here are worth more than the fermenter volume in the headline. Budget your time at a shared site accordingly: book it for the recovery problem, not for the growth curve you have already solved.
